| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
6-Hydroxy-4-methylcoumarin shows bioactivity related to its dissociation constant when binding to FK506 binding protein (FKBP) with a Kd value of 760,000.0 nM. This suggests FKBP may be a target, though with low affinity.
|
|---|---|
| ln Vitro |
In cell-free systems, the activity of 6-Hydroxy-4-methylcoumarin can be assessed by its ability to bind to FKBP. This binding affinity is measured using surface plasmon resonance or fluorescence-based assays. Its other activities are not typically measured in cell-free systems. In vitro, 6-Hydroxy-4-methylcoumarin inhibits the proliferation of cells by inhibiting DNA, RNA, and protein synthesis. This leads to the inhibition of cell growth and the induction of apoptosis in cancer cells. It has anticancer activity.
|
| ln Vivo |
In vivo, 6-Hydroxy-4-methylcoumarin has been shown to have anticancer activity in animal models. It inhibits the growth of tumors by inducing apoptosis and inhibiting cell proliferation. Further studies are needed to fully characterize its in vivo efficacy.
|
| Enzyme Assay |
In vitro, the binding of 6-Hydroxy-4-methylcoumarin to FKBP can be measured using a fluorescence polarization or surface plasmon resonance assay. The compound's affinity for the protein is determined by its dissociation constant (Kd).
|
| Cell Assay |
Cells are treated with 6-Hydroxy-4-methylcoumarin. Cell proliferation is measured using assays like MTT or BrdU incorporation. DNA, RNA, and protein synthesis are measured using radiolabeled precursors. Apoptosis is assessed by flow cytometry.
|
| Animal Protocol |
In vivo anticancer activity is evaluated in tumor xenograft models. Mice bearing tumors are treated with the compound, and tumor growth is monitored. Apoptosis and proliferation markers are assessed in tumor tissue by immunohistochemistry.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 6-Hydroxy-4-methylcoumarin are not well-documented. As a coumarin, its oral bioavailability may be variable. Its metabolism and excretion are not well-characterized. Further studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for 6-Hydroxy-4-methylcoumarin is limited. Its anticancer activity suggests it may have cytotoxic effects on cancer cells, but its selectivity and safety profile require further investigation.
|
| Additional Infomation |
6-Hydroxy-4-methylcoumarin is a research compound with potential anticancer activity. It is a valuable tool for studying the mechanisms of cell proliferation and apoptosis. It is not an approved drug and is for research use only.
|
| Molecular Formula |
C10H8O3
|
|---|---|
| Molecular Weight |
176.1687
|
| Exact Mass |
176.047
|
| CAS # |
2373-31-1
|
| PubChem CID |
75409
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
391.4±37.0 °C at 760 mmHg
|
| Melting Point |
246.5-249.5 °C(lit.)
|
| Flash Point |
181.8±19.3 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.611
|
| LogP |
2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
13
|
| Complexity |
257
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C([H])=C(C([H])([H])[H])C2C([H])=C(C([H])=C([H])C1=2)O[H])=O
|
| InChi Key |
IRUHWRSITUYICV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H8O3/c1-6-4-10(12)13-9-3-2-7(11)5-8(6)9/h2-5,11H,1H3
|
| Chemical Name |
6-hydroxy-4-methylchromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~567.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6763 mL | 28.3817 mL | 56.7634 mL | |
| 5 mM | 1.1353 mL | 5.6763 mL | 11.3527 mL | |
| 10 mM | 0.5676 mL | 2.8382 mL | 5.6763 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
